Skip to main content
NewslettersWatchlist

Marvel Biosciences Corp(MRVL-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.150
Day High0.150
Open:0.150
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Marvel Biosciences Corp down on Tuesday (MRVL)
AI-generated - The Globe and Mail
Marvel Biosciences: Top 10 Undervalued Biotechnology Industry Stocks (MRVL)
Newsfile
Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204
Newsfile
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204
Newsfile
Marvel Biosciences Announces Testing MB-204 on Autism by French University
AI-generated - The Globe and Mail
Marvel Biosciences: Top 10 Undervalued Biotechnology Industry Stocks (MRVL)
Newsfile
Marvel Biosciences Announces Closing of Non-Brokered Private Placement
Newsfile
Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel
Newsfile
Marvel Biosciences Invited to Test MB-204 on Autism by French University
AI-generated - The Globe and Mail
Marvel Biosciences: Top 10 Undervalued Biotechnology Industry Stocks (MRVL)
Baystreet
Stocks in play: Marvel Biosciences Corp
Newsfile
Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials
Baystreet
Stocks in play: Marvel Biosciences Corp
Newsfile
Marvel Highlights Key Asset at the 2023 Alzheimer's Association International Conference
Newsfile
Marvel Successfully Completes the Dog and Rat GLP Toxicology Studies Required to Enter Human Trials
Baystreet
Stocks in play: Marvel Biosciences Corp
BayStreet.ca
Help is on the Way as Rising Alzheimer’s Cases Highlight Urgency for New Treatments
Baystreet
Stocks in play: Marvel Biosciences Corp
Newsfile
Marvel Commences Final Study Required Prior to Initiating Human Trials
BayStreet.ca
With Alzheimer’s Cases Set to Explode in the Near-Term, New Treatments and Diagnostics are Needed
Baystreet
Stocks in play: Marvel Biosciences Corp
Newsfile
Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study
Baystreet
Stocks in play: Marvel Biosciences Corp
Newsfile
Marvel Biosciences Announces Closing of First Tranche of Debenture Offering
Baystreet
Stocks in play: Marvel Biosciences Corp
Newsfile
Marvel Biosciences Announces Proposed Debenture Offering
Baystreet
Stocks in play: Marvel Biosciences Corp
Newsfile
Marvel Biosciences Completes a Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer's Disease and Depression
Baystreet
Stocks in play: Marvel Biosciences Corp
Newsfile
Marvel Biosciences Successfully Completes its Short Term Dose Ranging Study in Rats and Dogs for MB-204
Baystreet
Stocks in play: Marvel Biosciences Corp
Baystreet
Stocks in play: Marvel Biosciences Corp

Profile

Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.